AUPH Aurinia Pharma: Earnings per share for the last twelve months

Aurinia Pharmaceuticals (AUPH) is focused on bringing drugs for autoimmune pathologies to market. The 12-month EPS trend confirms this trajectory, where 2.30 describes the current status of the metric. Business revenues rely on sales of a kidney drug and insurance coverage. Meanwhile, the stable legal climate in the US and Canada ensures the company's secure development.
Analytical breakdowns and data insights for company Aurinia Pharma (AUPH)

The high scientific potential of Aurinia Pharmaceuticals (AUPH) in the field of targeted kidney therapy requires significant R&D expenditures, which directly impacts the business's bottom-line profitability. The 12-month net income per share trend reflects a financial result adjusted for issuance volume, allowing investors to assess the real capitalization vector and the company's margin stability through daily monitoring of annual earnings momentum.